Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Target

Recursion Pharmaceuticals is supported by encouraging clinical progress in REC-4881, where consistent total and upper GI polyp reductions, durability through 25 weeks, and manageable safety strengthen confidence in its FAP program and near-term registrational potential. The company’s broader AI platform is also gaining credibility through REC-1245’s early monotherapy activity in heavily pretreated solid tumors, while its ClinTech capabilities have shown ~1.5-fold faster enrollment versus historical benchmarks, suggesting an execution advantage in future studies. Financially, partner validation remains meaningful, highlighted by a $10M Sanofi milestone and total payments of $144M under that collaboration, alongside eligibility for more than $300M in additional milestones and low double-digit royalties.

Recursion Pharmaceuticals is facing elevated fundamental risk because its clinical programs remain in relatively early Phase I/II development, leaving a high chance that candidates fail to generate meaningful clinical success or regulatory approval. The company also competes in an increasingly crowded ML/AI drug-discovery field, where it may struggle to lead the market, secure new partnerships, or prove that RecursionOS can reliably produce biologically relevant leads. Financially, it is likely to need additional funding to expand the platform and advance candidates through trials, and there is no assurance that financing will be available on favorable terms or that existing partnerships will meaningfully contribute revenues.